Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.49 |
| ▸ | RELA | Q04206 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31401245 | 1.00 | FOLH1 (0.58) | FOLH1MRGPRX4TP53PKMNFKB1 | |
| SCHEMBL11816773 | 0.86 | ALDH1A1 (0.51) | MRGPRX4SMN1; SMN2 | |
| SCHEMBL6011976 | 0.84 | FOLH1 (0.56) | FOLH1MRGPRX4TP53PKMNFKB1 | |
| SCHEMBL29108709 | 0.84 | FOLH1 (0.59) | FOLH1CA1CA2CA9CYP2D6 | |
| SCHEMBL7393646 | 0.82 | FOLH1 (0.58) | FOLH1MRGPRX4TP53NFKB1NFKB2 | |
| SCHEMBL22623401 | 0.82 | FOLH1 (0.58) | FOLH1MRGPRX4CA1CA2CA9 | |
| SCHEMBL31720548 | 0.82 | FOLH1 (0.58) | FOLH1CA1CA2CA9CYP2D6 | |
| SCHEMBL35360 | 0.81 | LOXL2 (0.64) | FOLH1MRGPRX4SMN1; SMN2CA1CA2 | |
| SCHEMBL5304881 | 0.81 | FOLH1 (0.53) | FOLH1MRGPRX4TP53PKMNFKB1 | |
| SCHEMBL27993553 | 0.80 | LOXL2 (0.46) | MRGPRX4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-11458124-B2 | Spirocyclic indane analogues as IL-17 modulators | UCBBiopharma Srl (BE) | 2022-10-04 | — | — | US | disclosed |
| US-20210228547-A1 | Spirocyclic Indane Analogues as IL-17 Modulators | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2021-07-29 | — | — | US | disclosed |
| EP-3820567-A1 | SPIROCYCLIC INDANE ANALOGUES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2021-05-19 | — | — | EP | disclosed |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| CN-112334192-A | Spirocyclic indane analogs as IL-17 modulators | UCB生物制药有限责任公司 | 2021-02-05 | — | — | CN | disclosed |
| US-20200190030-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| WO-2020011731-A1 | SPIROCYCLIC INDANE ANALOGUES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-01-16 | — | — | WO | disclosed |
| US-20180258043-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| EP-1322611-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-07-02 | — | — | EP | disclosed |
| US-20030119810-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | AVENTIS PHARMA S.A. (FR) | 2003-06-26 | — | — | US | disclosed |
| US-6566356-B2 | 3-amido or 3-sulfonylamino azetidine compounds and their preparation; high affinity for cannabinoid receptor CB1 type, useful in treating central nervous system, immune, gastrointestinal or cardiovascular disorders, drug abuse | AVENTIS PHARMA S.A. (FR) | 2003-05-20 | — | — | US | disclosed |
| US-20030055033-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ACHARD DANIEL (FR) | 2003-03-20 | — | — | US | disclosed |
| US-6518264-B2 | For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders | AVENTIS PHARMA S.A. (FR) | 2003-02-11 | — | — | US | disclosed |
| US-6479479-B2 | 1-DIARYLMETHYL-4-ALKYL OR ALKYLSULFONYLALKYL-AZETIDINES; CANNABINOID RECEPTOR ANTAGONISTS; NERVOUS SYSTEM DISORDERS (CNS); CARDIOVASCULAR AND GLANDULAR DISORDERS; DRUG ABUSE; PSYCHOLOGICAL DISORDERS; | AVENTIS PHARMA S.A. (FR) | 2002-11-12 | — | — | US | disclosed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | disclosed |
| WO-2002020484-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
| US-20020019383-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | US | disclosed |
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2001-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228547-A1 | Spirocyclic Indane Analogues as IL-17 Modulators | IL17A, IL18, IL23R | FOLH1 3604/4885MRGPRX4 2400/4885TP53 2999/4885 |
| US-20200190030-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | FOLH1 2409/4885MRGPRX4 401/4885TP53 758/4885 |
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | FOLH1 4467/4885MRGPRX4 974/4885TP53 3337/4885 |
| US-20020019383-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | HRH2, ALK, HRH1 | FOLH1 4209/4885MRGPRX4 746/4885TP53 4746/4885 |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | FOLH1 2409/4885MRGPRX4 401/4885TP53 758/4885 |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | SHH, GLI1, SMO | FOLH1 2528/4885MRGPRX4 437/4885TP53 775/4885 |
| US-20030055033-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | FOLH1 4467/4885MRGPRX4 974/4885TP53 3337/4885 |
| US-20030119810-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | ALK, HRH2, HRH1 | FOLH1 4388/4885MRGPRX4 829/4885TP53 4832/4885 |
| US-11458124-B2 | Spirocyclic indane analogues as IL-17 modulators | IL17A, IL18, IL23R | FOLH1 3604/4885MRGPRX4 2400/4885TP53 2999/4885 |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | FOLH1 2409/4885MRGPRX4 401/4885TP53 758/4885 |
| US-20180258043-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | FOLH1 2409/4885MRGPRX4 401/4885TP53 758/4885 |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | FOLH1 4446/4885MRGPRX4 1071/4885TP53 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.